Active Ingredient History

NOW
  • Now
Cenobamate (also known as YKP3089) is a small molecule sodium channel blocker in development for the treatment of partial-onset seizures in adult patients. In mice and rats, Cenobamate displayed an anticonvulsant activity in the maximal electroshock test and prevented seizures induced by chemical convulsants such as pentylenetetrazol and picrotoxin. In addition, Cenobamate was reported to be effective in two models of focal seizure, the hippocampal kindled rat and the mouse 6 Hz psychomotor seizure models. Two completed adequate and well-controlled clinical studies demonstrated a significant reduction in focal seizures with Cenobamate in patients with epilepsy, and a long-term open-label phase 3 safety clinical trial is currently ongoing. Cenobamate is considered a new generation antiepileptic therapy and clinical trials have shown that it may be more effective and safer than existing drugs. If licensed, Cenobamate will offer a new adjunctive treatment option for patients with partial focal epilepsy.   NCATS

  • SMILES: NC(=O)O[C@@H](CN1N=CN=N1)C2=CC=CC=C2Cl
  • InChIKey: GFHAXPJGXSQLPT-VIFPVBQESA-N
  • Mol. Mass: 267.672
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Drug Pricing (per unit)

United States

$24.3277 - $32.6680
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue